BNR
Burning Rock Biotech Ltd.
NASDAQ · Healthcare · Medical - Diagnostics & Research · CN
$11.42
−6.85%Year over year
Reported trailing growth
- Revenue
- -6.6%
- EBITDA
- +42.1%
- EBIT
- +55.8%
- EPS
- +52.3%
- Free cash flow
- +79.3%
- Operating cash flow
- +84.5%
Forward estimates
Based on analyst estimates
- Revenue
- +13.6%
- EBITDA
- -29.7%
- EPS
- -4.1%
Three-year CAGR
- Revenue
- -1.4%
- EBITDA
- +88.2%
- EBIT
- +84.7%
- Net income
- +84.0%
- EPS
- -47.3%
- Free cash flow
- +65.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026